GALE

UDP-glucose 4-epimerase · Q14376 · GALE on Sugi Atlas →

953 patent compounds predicted against GALE, 718 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Haloprogin (SCHEMBL3649)	1.00	1/20
Ethacrynic Acid (SCHEMBL26353)	1.00	1/20
Ebselen (SCHEMBL33829)	1.00	1/20
Ebselen (SCHEMBL4406056)	1.00	1/20
Haloprogin (SCHEMBL8165340)	1.00	1/20
Ethacrynic Acid (SCHEMBL9108011)	1.00	1/20
Ethacrynic Acid (SCHEMBL905726)	0.97	1/20
Ethacrynic Acid (SCHEMBL2482896)	0.97	1/20
Ethacrynic Acid (SCHEMBL3713733)	0.97	1/20
Ebselen (SCHEMBL19064566)	0.96	1/20
Ebselen (SCHEMBL20477111)	0.96	1/20
Ebselen (SCHEMBL20678555)	0.96	1/20
Ethacrynic Acid (SCHEMBL18263238)	0.86	1/20
Ethacrynic Acid (SCHEMBL8907134)	0.84	1/20
SCHEMBL10001217	0.81	1/20
SCHEMBL10543330	0.81	1/20
SCHEMBL3713736	0.80	1/20
SCHEMBL10014667	0.80	1/20
SCHEMBL10031684	0.80	1/20
SCHEMBL9717560	0.80	1/20

Clinical trials — most relevant to GALE by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sialic Acid in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)	PHASE3	COMPLETED
The Role of SGLT2i in Management of Moderate AS	PHASE2/PHASE3	UNKNOWN
Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3	PHASE3	COMPLETED
Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia	PHASE3	COMPLETED
NAlmefene Versus Placebo in Addition to Treatment as Usual on Craving in Behavioural Addictions	PHASE3	RECRUITING
The Effect of Triheptanoin on Fatty Acid Oxidation and Exercise Tolerance in Patients With Glycogenoses	PHASE2	COMPLETED
An Open Label Phase 2 Extension Study of Higher Dose Sialic Acid-Extended Release (SA-ER) Tablets and Sialic Acid-Immediate Release (SA-IR) Capsules in Patients With Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy	PHASE2	COMPLETED
Endocalyx for Heart Failure	PHASE2	RECRUITING
Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients	PHASE2	ENROLLING_BY_INVITATION
Efficacy Study of Daily Administration of VPA in Patients Affected by Wolfram Syndrome	PHASE2	UNKNOWN
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer	PHASE1/PHASE2	COMPLETED
Multi-Center Study of ManNAc for GNE Myopathy	PHASE2	ACTIVE_NOT_RECRUITING
A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis	PHASE2	COMPLETED
Efficacy and Safety of Magnesium Vitamin B6 in First Episode Bipolar Disorder	PHASE2	RECRUITING
Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy	PHASE1	COMPLETED
Phase 1 Clinical Trial to Evaluate the Effect of DWP14012 on the Pharmacokinetics of DWC202201 in Healthy Subjects	PHASE1	UNKNOWN
Phase I Clinical Trial of ManNAc in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)	PHASE1	COMPLETED
Clinical, Biological and NMR Outcome Measures Study for Hereditary Inclusion Body Myopathy Due to Mutation of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine Kinase Gene (GNE)	nan	COMPLETED
Glycosylation in Patients With Galactosaemia	nan	COMPLETED
A Natural History Study of Patients With GNE Myopathy and GNE-Related Diseases	nan	COMPLETED
Effect of Lactose on Blood Lipids	nan	COMPLETED
Intervention and Outcomes in Duarte Galactosemia	nan	COMPLETED
Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation	nan	COMPLETED
Post Marketing Registry to Assess Usage, Safety and Effectiveness of Deltyba Tablets in Korean Patients With MDR-TB	nan	COMPLETED
Galactose Mediated Glycogen Resynthesis	nan	COMPLETED
The Natural History of Alpha-Mannosidosis	nan	COMPLETED
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)	nan	WITHDRAWN
Biomarker for Pompe Disease (BioPompe)	nan	WITHDRAWN
Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease Cardiomyopathy	nan	UNKNOWN
Registry Gangliosidoses	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a GALE binder may also engage these)

Protein	Name	Similarity
Q3T105	—	1.000	Q3T105 →
Q8R059	—	0.998	Q8R059 →
P18645	—	0.997	P18645 →
Q5R8D0	—	0.996	Q5R8D0 →
P56985	—	0.996	P56985 →
P56986	—	0.995	P56986 →
P56997	—	0.992	P56997 →
Q9F7D4	—	0.990	Q9F7D4 →
P24325	—	0.987	P24325 →
P22715	—	0.986	P22715 →
Q42605	—	0.986	Q42605 →
Q56093	—	0.986	Q56093 →
P35673	—	0.986	P35673 →
Q43070	—	0.986	Q43070 →
Q8LNZ3	—	0.986	Q8LNZ3 →
Q59678	—	0.985	Q59678 →
Q05026	—	0.984	Q05026 →
P09147	—	0.984	P09147 →
Q9CNY5	—	0.983	Q9CNY5 →
Q553X7	—	0.982	Q553X7 →
Q8LDN8	—	0.982	Q8LDN8 →
Q9T0A7	—	0.982	Q9T0A7 →
P55180	—	0.981	P55180 →
Q9C7W7	—	0.981	Q9C7W7 →
Q9SN58	—	0.981	Q9SN58 →
A3QJB2	—	0.981	A3QJB2 →
Q652A8	—	0.980	Q652A8 →
B8CVJ3	—	0.980	B8CVJ3 →
B0M3E8	—	0.979	B0M3E8 →
Q564Q1	—	0.979	Q564Q1 →